Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y12 receptor inhibitors

Mark J. Antonino, Young Hoon Jeong, Udaya S. Tantry, Kevin P. Bliden, Paul A. Gurbel

Research output: Contribution to journalReview articlepeer-review

Abstract

Therapy with clopidogrel and aspirin, commonly known as dual antiplatelet therapy, is a widely adapted secondary prevention strategy among coronary artery disease patients treated with percutaneous coronary intervention. However, in addition to response variability and high on-treatment platelet reactivity and their relation to increased adverse events during clopidogrel therapy, candidate gene studies and genome-wide association studies have highlighted the significance of single nucleotide polymorphisms of genes associated with clopidogrel metabolism in coronary artery disease patients. Genotyping may have an emerging role in personalized antiplatelet therapy, particularly with the advent of new P2Y12 receptor blockers that have more rapid and potent pharmacodynamic properties than clopidogrel. The current review discusses the role of genotyping in personalizing P2Y12 receptor-blocker therapy.

Original languageEnglish (US)
Pages (from-to)1011-1022
Number of pages12
JournalExpert review of cardiovascular therapy
Volume10
Issue number8
DOIs
StatePublished - Aug 1 2012

Keywords

  • P2Y receptor blockers
  • coronary artery disease
  • genotyping

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y<sub>12</sub> receptor inhibitors'. Together they form a unique fingerprint.

Cite this